Prognostic Biomarkers in Tumor Tissue Samples From Young Patients With Neuroblastoma
Recruitment status was Active, not recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify biomarkers and learn more about biomarkers related to cancer.
PURPOSE: This research study is studying biomarkers in tumor tissue samples from young patients with neuroblastoma.
| Condition | Intervention |
|---|---|
|
Neuroblastoma |
Genetic: microarray analysis Genetic: protein expression analysis Other: immunoenzyme technique Other: laboratory biomarker analysis |
| Study Type: | Observational |
| Official Title: | Expression of Ubiquitin Carboxyl-Terminal Hydrolase 1 (UCHL1) in Neuroblastoma Cancer Stem Cells and Its Relationship to Patient Prognosis |
- UCHL1 as an indirect marker of cancer stem cells [ Designated as safety issue: No ]
- UCHL1 as a biomarker of neuroblastoma prognosis [ Designated as safety issue: No ]
| Estimated Enrollment: | 90 |
| Study Start Date: | May 2011 |
| Estimated Primary Completion Date: | August 2011 (Final data collection date for primary outcome measure) |
OBJECTIVES:
- Determine whether ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) expression is an indirect cancer stem cell marker in pediatric patients with neuroblastoma.
- Correlate UCHL1 expression with staging information and patient's outcome.
OUTLINE: Archived tissue microarray samples are analyzed for ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) expression by UCHL1 monoclonal antibody and peroxidase technique. Results are then compared with patients' clinical data, including age at diagnosis, race, date of diagnosis, histology, stage and location at diagnosis, presence of cancer predisposition, date of completion of treatment, surgery performed, type of chemotherapy received, history of recurrence, and status (alive with disease, alive without disease, dead), if available.
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
- Diagnosed with neuroblastoma
- Tissue microarrays containing normal and neuroblastoma samples provided by the Children's Oncology Group (COG) Biopathology Center
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- Not specified
Contacts and Locations
More Information
Additional Information:
No publications provided
| Responsible Party: | Gregory H. Reaman, Children's Oncology Group - Group Chair Office |
| ClinicalTrials.gov Identifier: | NCT01358617 History of Changes |
| Other Study ID Numbers: | CDR0000700618, COG-ANBL11B3 |
| Study First Received: | May 19, 2011 |
| Last Updated: | May 26, 2011 |
| Health Authority: | United States: Federal Government |
Keywords provided by National Cancer Institute (NCI):
|
disseminated neuroblastoma localized resectable neuroblastoma recurrent neuroblastoma stage 4S neuroblastoma localized unresectable neuroblastoma |
Additional relevant MeSH terms:
|
Neuroblastoma Neuroectodermal Tumors, Primitive, Peripheral Neuroectodermal Tumors, Primitive Neoplasms, Neuroepithelial Neuroectodermal Tumors |
Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue |
ClinicalTrials.gov processed this record on May 19, 2013